Anna Protopapas

Anna Protopapas, listed as chief executive, has filed trades across 4 companies (mainly through SEC (Form 4)), most often in Mersana Therapeutics, Inc., Nuvalent, Inc. and Ariad Pharmaceuticals Inc. In total, 16 filings cover trades dated from 1 February 2016 to 15 July 2026.

No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Grants and option exercises follow pay plans set in advance, so they reveal less about an insider's own view than a purchase made with personal money.

The latest filing, published on 15 July 2026, reports a transaction in Nuvalent, Inc. Typically, a trade is published a median of 2 days after it takes place. Section 16 rules allow two business days to file each Form 4. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.